Katja Krauss

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 162 citations

Breast Oncology, Medicine, Neoadjuvant Dual Blockade +8

Acute coronary insufficiency. Course and follow-up

Katja Krauss · Archives of Internal Medicine · 1972 · 79 citations

Heart Failure, Prolonged Coronary Pain, Cardiovascular Disease +15

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser et al. · The Lancet Oncology · 2022 · 76 citations

Breast Oncology, Medicine, Trastuzumab Therapy +9

Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.

Hans‐Georg Kopp, Katja Krauss, Tanja Fehm et al. · PubMed · 2011 · 70 citations

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Ulrike Nitz, Oleg Gluz, Hans Kreipe et al. · Therapeutic Advances in Medical Oncology · 2020 · 44 citations · Full text